ERLEADA Revolutionizes Prostate Cancer Treatment Strategy

Johnson & Johnson's new study just flipped the script on prostate cancer treatment. Their drug, ERLEADA, when used before and after surgery alongside hormone therapy, significantly reduced the risk of cancer spreading or causing death by 20%. Patients were also nine times more likely to have little to no cancer remaining after surgery. This breakthrough offers a hopeful new approach for tackling high-risk prostate cancer. What does it mean for you? If prostate cancer is on your radar, this could mean fewer follow-up treatments and a longer stretch before needing additional therapy, which is a big win for patients dealing with this aggressive disease.